BioBridge Collagen Matrix
Surgical treatment of secondary lymphedema / Soft tissue repair
Approved/CommercialActive
Key Facts
Indication
Surgical treatment of secondary lymphedema / Soft tissue repair
Phase
Approved/Commercial
Status
Active
Company
About FibrAlign
FibrAlign is a privately-held, commercial-stage biotech company leveraging its proprietary Nanoweave® scaffolding platform to develop therapeutic devices for tissue regeneration. The company's lead product, BioBridge, is already commercially available in multiple regions for lymphedema treatment, having been used in over 750 surgeries globally. Backed by grant funding and strategic partnerships, FibrAlign is advancing a pipeline of novel products while navigating the regulatory complexities of a device indicated for a chronic condition with no cure.
View full company profile